Hodgkin's lymphoma therapy: past, present, and future

Area of Science:

• Oncology
• Hematology
• Radiotherapy
• Systemic Chemotherapy

Background:

• Hodgkin's lymphoma (HL) treatment has significantly advanced, achieving high cure rates.
• Current research prioritizes minimizing long-term toxicity while maintaining treatment efficacy.
• Accurate identification of aggressive HL through prognostic factors is crucial for tailored strategies.

Purpose of the Study:

• To review prognostic tools for identifying aggressive Hodgkin's lymphoma.
• To discuss current and future therapeutic strategies for HL management.
• To highlight the role of PET scanning and biomarkers in risk stratification.

Main Methods:

• Literature review of publications from the last two decades.
• Analysis of prognostic factors including pathology, clinical, biologic, and radiologic data.
• Evaluation of combined modality therapy, systemic chemotherapy, and response-adapted strategies.

Main Results:

• Comprehensive review of risk assessment strategies in HL.
• Overview of current and investigational therapeutic approaches for HL.
• Discussion on the utility of PET scanning and biomarkers for patient identification.

Conclusions:

• Effective risk assessment in HL is essential for maximizing outcomes and minimizing toxicity.
• Response-adapted therapy, particularly using PET, shows promise for improving HL treatment.
• Minimizing long-term toxicity is a key consideration in current and future HL management.